Hilal Taymaz-Nikerel

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Saccharomyces Cerevisiae

Gene Expression

Chronic Myeloid Leukemia

Top Venues

Molecular omics

The pharmacogenomics journal

Turkish journal of biology = Turk biyoloji dergisi

This page only lists publications with an associated author ORCID identifier.

Publications

Mitzi de la Cruz, Flavio Kunert, Hilal Taymaz-Nikerel, Juan-Carlos Sigala, Guillermo Gosset, Jochen Büchs, Alvaro R Lara
Increasing the Pentose Phosphate Pathway Flux to Improve Plasmid DNA Production in Engineered E. coli . Microorganisms 12 (1) (2024)
Mitzi de la Cruz, Flavio Kunert, Hilal Taymaz-Nikerel, Juan-Carlos Sigala, Guillermo Gosset, Jochen Büchs, Alvaro R Lara
Increasing the Pentose Phosphate Pathway Flux to Improve Plasmid DNA Production in Engineered E. coli . Microorganisms 12 (1) (2024)
Mitzi de la Cruz, Flavio Kunert, Hilal Taymaz-Nikerel, Juan-Carlos Sigala, Guillermo Gosset, Jochen Büchs, Alvaro R Lara
Increasing the Pentose Phosphate Pathway Flux to Improve Plasmid DNA Production in Engineered E. coli . Microorganisms 12 (1) (2024)
Muhammed Erkan Karabekmez, Hilal Taymaz-Nikerel, Serpil Eraslan, Betul Kirdar
Time-dependent re-organization of biological processes by the analysis of the dynamic transcriptional response of yeast cells to doxorubicin. Molecular omics 17 (4) (2022)
Hilal Taymaz-Nikerel, Alvaro R Lara
Vitreoscilla Haemoglobin: A Tool to Reduce Overflow Metabolism. Microorganisms 10 (1) (2021)
Arzu Cakir, Melisa Tuncer, Hilal Taymaz-Nikerel, Özlem Ulucan
Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection. The pharmacogenomics journal 21 (6) (2021)
Hilal Taymaz-Nikerel
Doxorubicin-induced transcriptome meets interactome: identification of new drug targets. Turkish journal of biology = Turk biyoloji dergisi 46 (2) (2021)
Hilal Taymaz-Nikerel
Integration of fluxome and transcriptome data in Saccharomyces cerevisiae offers unique features of doxorubicin and imatinib. Molecular omics 17 (5) (2021)